- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07650201
Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction
A Prospective, Multicenter, Open-label, Single-arm Clinical Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) IOL for Correction of Aphakia Following Cataract Extraction
This study is designed to evaluate how well an artificial lens, called an intraocular lens (IOL), performs in adults undergoing cataract surgery. During cataract surgery, the eye's natural lens is removed and replaced with an artificial lens to improve vision.
The main goal of the study is to evaluate participants' vision after the IOL is placed in the eye. Approximately one year after surgery, participants' vision will be assessed to determine how clearly they can see.
The results of this study will provide additional information about the performance of the IOL in adults undergoing cataract surgery.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Director, Clinical Operations
- Telefonnummer: 919-433-1600
- E-post: Clinical@KowaUS.com
Studieorter
-
-
California
-
Beverly Hills, California, Förenta staterna, 90210
- Rekrytering
- Beverly Hills Institute of Ophthalmology
-
-
Colorado
-
Grand Junction, Colorado, Förenta staterna, 81501
- Rekrytering
- Icon EyeCare
-
-
Georgia
-
Gainesville, Georgia, Förenta staterna, 30501
- Rekrytering
- North Georgia Eye Associates
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63128
- Rekrytering
- Ophthalmology Consultants Ltd
-
-
South Carolina
-
Mt. Pleasant, South Carolina, Förenta staterna, 29464
- Rekrytering
- Carolina Eyecare Physicians
-
-
Texas
-
Houston, Texas, Förenta staterna, 77008
- Rekrytering
- Houston Eye Associates, North Loop
-
Houston, Texas, Förenta staterna, 77027
- Rekrytering
- Berkeley Eye
-
Hurst, Texas, Förenta staterna, 76054
- Rekrytering
- Texas Eye Research
-
-
Virginia
-
Lynchburg, Virginia, Förenta staterna, 24502
- Rekrytering
- Piedmont Eye Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Are able and willing to provide written informed consent, attend all scheduled visits, and comply with all trial procedures and follow-up
- Have a study eye with visually significant cataract for which phacoemulsification cataract extraction and posterior chamber IOL implantation is indicated
- Meet all other inclusion criteria outlined in the clinical study protocol
Exclusion Criteria:
- Have serious systemic disease that could increase operative risk or conditions that can confound the surgical outcome
- Within 30 days of the Screening Visit, use of systemic medications with significant ocular side effects or any medications that could confound the outcome or increase participant risk
- Meet any other exclusion criteria outlined in the clinical study protocol
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: KI-362-US1
Participants receive an intraocular lens (IOL) implanted during cataract surgery to replace the natural lens of the eye. The IOL is delivered using a single-use, preloaded delivery device and positioned within the eye's natural lens capsule. |
Injector and one-piece (1P) monofocal IOL |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of Participants Achieving a Predefined BCDVA Criterion at Visit 5
Tidsram: Baseline through Visit 5, approximately Days 330-390.
|
Proportion of participants achieving a predefined best-corrected distance visual acuity (BCDVA) criterion, as measured using Early Treatment Diabetic Retinopathy Study (ETDRS) illuminated charts at postoperative days 330-390 (Visit 5, Form 5). |
Baseline through Visit 5, approximately Days 330-390.
|
|
Proportion of Participants With Selected Ocular Adverse Events
Tidsram: Baseline through end of study (up to 15 months)
|
Proportion of participants experiencing one or more predefined ocular adverse events following treatment, including both cumulative and persistent events. Events are assessed based on their occurrence or persistence during the study period. |
Baseline through end of study (up to 15 months)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Shona Pendse, MD, MMSc, Kowa Research Institute, Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- KI-362-US1-301
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .